Tech Company Financing Transactions
Engimmune Therapeutics Funding Round
On 5/3/2022, Engimmune Therapeutics raised $15.5 million in Seed financing from Novo Ventures, Pureos Bioventures and private investors.
Transaction Overview
Company Name
Announced On
5/3/2022
Transaction Type
Venture Equity
Amount
$15,500,000
Round
Seed
Investors
Novo Ventures (Lead Investor)
Pureos Bioventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further build its pipeline, expand the research team in Switzerland and build a presence in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Basel, Undisclosed
Switzerland
Basel, Undisclosed
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
Engimmune was co-founded in 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof. Sai Reddy and Dr. Søren Mouritsen based on inventions by Dr. Vazquez-Lombardi, who serves as the company CSO, and Prof. Reddy, who serves on the Scientific Advisory Board.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Bent Jakobsen
Chief Executive Officer
Søren Mouritsen
Chief Scientific Officer
Rodrigo Vazquez-Lombardi
Co-Founder
Sai Reddy
Browse more venture capital transactions:
Prev: 5/3/2022: Henry venture capital transaction
Next: 5/3/2022: Inflection.io venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs